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Abstract 
Objectives: To describe demographics and outcomes of 
a new sclerotherapy service – Foam sclerotherapy (FS), for 
venous disease at Mater Dei Hospital, Malta 
Methods: The data of a consecutive series of patients 
undergoing FS were prospectively entered into a database 
and the results analysed.  Medical notes of patients were 
also reviewed. Patients underwent detailed venous duplex 
scanning before and after each intervention and at follow-
up visits. 
Results: 121 patients underwent a total of 204 FS 
procedures between November 2008 and October 2011. 
22% were male and 78% of the procedures were done in 
female patients. 151 (74%) of procedures were done in 
patients above the age of 50 years. 74(37%) interventions 
were for recurrent varicose veins and 113(55%) for 
chronic venous insufficiency (CEAP4-6). 77 (38%) 
patients had active or healed venous ulceration as the 
indication for treatment. 83% of ulcers healed after 
foam sclerotherapy during the follow up period.  
88.3% (143/162) of veins treated were completely 
occluded while 11.7% (19/162) were partially 
occluded.  In the majority (64%) only one treatment 
session was required. One patient sustained an 
anaphylactic reaction to the sclerosant.  No deep vein 
thromboses, cardiovascular events, pulmonary 
embolism or other major complications were reported.  
Skin staining was reported in 21.5% of cases.  
Conclusions: Foam sclerotherapy is a safe and 
cheap treatment modality resulting in high rates of 
venous ulcer healing and successful venous occlusion 
and a very low complication rate. The success rate of 
foam sclerotherapy in Malta is comparable to that 
reported in the literature. 
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Introduction 
Lower-extremity venous insufficiency is a common 
medical condition and occurs in about 15% of men and 
35% of women.
1,2,3
 The effect of venous insufficiency 
on patients’ health-related quality of life (HRQOL) is 
substantial and comparable with other common 
chronic diseases such as arthritis, diabetes, and 
cardiovascular disease.
4
 Foam sclerotherapy is 
increasingly being used for the treatment of all 
categories of venous disease.  It involves the 
transformation of liquid sclerosant into a foam, by 
mixing the sclerosant with air or other gas, and 
injection of the foam into veins of the lower limb often 
under ultrasound control.  The sclerosant induces an 
inflammatory response in the vein which leads to 
occlusion of the vein. The objective of treating 
incompetent veins with foam sclerotherapy is to 
induce thrombosis and occlusion of the veins through 
which reflux occurs. 
The indications for treatment vary widely between 
uncomplicated varicose veins to venous ulceration.  
Venous disease of the lower limbs is extremely 
common, is an important cause of morbidity and 
consumes a significant proportion of resources of any 
health care system in developed countries.  Treatment 
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for venous disease includes traditional open surgery, 
endovenous laser ablation or endovenous radiofrequency 
ablation, amongst others.  Foam sclerotherapy forms part 
of the clinician’s armamentarium in dealing with venous 
disease.  Foam sclerotherapy has been shown to be 
effective in inducing occlusion of veins treated and has 
been found to be as effective as traditional surgical 
stripping. 
The major advantages of foam sclerotherapy are that it 
is cheap, does not require any anaesthetic and can be 
performed as an office procedure in a very short time.  It is 
also acceptable to patients and can be repeated as 
necessary. A systematic review on foam sclerotherapy 
showed that serious adverse events from this type of 
treatment are rare.
5
 
A foam sclerotherapy service was introduced to the 
Maltese health service in October 2008 after approval was 
obtained from the local health authorities and the 
sclerosant was procured.  The UK National Institute of 
Clinical Excellence (NICE) recommends that clinicians 
undertaking the procedure make special arrangements for 
audit. The aim of this study was to report the 
demographics and the outcomes of this newly introduced 
service for treatment of venous disease at Mater Dei 
Hospital, Malta. 
 
Method 
Patients referred to the vascular clinic at Mater Dei 
Hospital underwent a full assessment including history, 
examination and a complete lower limb venous duplex 
scan at their first visit.  The venous duplex scan assessed 
patency and competency of deep and superficial veins of 
the lower limb affected. A Philips HD11 ultrasound 
scanner was used and all scans were performed by one 
experienced vascular ultrasonographer. Sites of 
incompetence were identified and duration of reflux 
measured in affected veins.  Patients were offered foam 
sclerotherapy as a treatment option in cases of 
saphenofemoral incompetence, saphenopopliteal 
incompetence, perforator incompetence, recurrent 
saphenofemoral incompetence, recurrent saphenopopliteal 
incompetence and pelvic incompetence. 
Foam sclerotherapy was performed at the one-stop 
vascular clinic or at the foam sclerotherapy clinic held at 
the Day Case Unit at Mater Dei Hospital.  Depending on 
the source of incompetence, patients underwent venous 
cannulation under vision or under ultrasound control using 
either a 20 gauge intravenous cannula or a 25 gauge 
butterfly needle.  Confirmation of cannulation of the vein 
being treated was through ultrasound visualisation of the 
needle or cannula as well as through satisfactory back 
bleeding.  1% or 3% sodium tetradecyl sulphate was used.  
2mls of the sclerosant was mixed with 6mls of air using a 
three way tap and two 5ml Luer lock syringes using the 
Tessari technique.  A maximum of 8mls of foam generated 
in this way was used in a single session. In exceptional 
cases bigger volumes were used. The foam produced 
was then injected into the vein through the needle or 
cannula while the patient was requested to move the 
toes of the limb being treated.  Correct injection of the 
sclerosant into the vein was confirmed by observation 
of a snowstorm appearance in the respective veins on 
ultrasound scanning.  The treated leg was then 
bandaged using wadding, a crepe bandage and a 
cohesive bandage.  Patients were instructed to keep the 
bandaging on for 24 hours and then to replace the 
bandages with a class II full length stocking which 
they were instructed to wear day and night for 5 days 
and then during the day for a further 2 weeks. 
Patients were reviewed at the foam sclerotherapy 
clinic or the vascular clinic six to eight weeks after the 
initial treatment.  Patients were asked about symptoms 
and complications after their treatment. A clinical 
examination focused on the limb to assess skin 
staining, paraesthesia, and ulceration. A venous duplex 
scan was repeated and included assessment of the deep 
and superficial veins in the treated leg.  Based on the 
ultrasound scan and the clinical findings a decision 
was taken whether further sclerotherapy was required 
and if so with the patient’s consent further foam 
sclerotherapy was performed.   Occlusion of veins 
treated was confirmed by incompressibility on 
ultrasound and absence of colour flow in response to 
augmentation. 
The details of all consecutive patients who 
underwent foam sclerotherapy between November 
2008 and October 2011 were entered into the vascular 
database (Access 2000).  Data was collected on 
patients’ age, date of procedure, C part of CEAP 
classification, the indication for intervention, presence 
of chronic venous insufficiency including ulceration, 
the source of reflux, concentration and volume of 
sclerosant used, efficacy of treatment and any 
complications. 
The medical notes of patients entered into the 
database were reviewed in order to identify any late 
complications.    
 
Results 
One hundred and twenty one (121) patients 
underwent two hundred and four (204) foam 
sclerotherapy treatments for venous disease during the 
study period.  
Twenty two percent (22%) (n=45) of the patients 
treated were males and seventy eight percent (78%) 
(n=159) of the procedures were done in female 
patients. 
The age of patients treated varied between 24 and 
89 years with a median age of 58 years (Figure 1). 151 
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procedures (74%) were done in patients above the age of 
50 years. 
The CEAP classification for chronic venous disorders 
was used to classify venous disease in this cohort. The 
CEAP classification below was used
6
: 
 
C0: No visible or palpable signs of venous disease 
C1: Telangectasies or reticular veins 
C2: Varicose veins; distinguished from reticular veins by 
a diameter of 3mm or more. 
C3: Oedema. 
C4: Changes in skin and subcutaneous tissue secondary 
to CVD, now divided in 2 subclasses to better 
define the differing severity of venous disease. 
C4a: Pigmentation or eczema. 
C4b: Lipodermatosclerosis or atrophie blanche. 
C5: Healed venous ulcer. 
C6: Active venous ulcer. 
 
 
Figure 1: Number of procedures performed in each age group 
 
 
Figure 2: Number of patients undergoing foam sclerotherapy in 
each CEAP group 
Four (1.96%) procedures were done for C1 disease,  
80 (39.22%) procedures were done for C2 disease, 7 
(3.43%) procedures for C3 disease, 38 (18.63%) 
procedures for C4a disease, 20 (9.80%) procedures for 
C4b disease, 16 (7.84%) procedures for C5 disease 
and 39 (19.12%) procedures for C6 disease (Figure 2). 
Twenty one percent (n=42) of the procedures were 
done in patients with active ulceration and 35 (29%) 
patients had healed ulcers at the time of treatment. 
Sixty three percent (n=129) of procedures were 
done for primary venous disease and 37% (n=75)of 
procedures were treated for recurrent varicose veins. 
The source of incompetence was the saphenofemoral 
junction in 117 (57.35%) procedures, at the 
saphenopopliteal junction in 11 (5.39%) procedures, 
perforator incompetence in 23 (11.27%) procedures, 
pelvic incompetence in 44 (21.57%) procedures and 
26 (12.75%) of the procedures, the incompetence was 
at other anatomical locations (Figure 3). Some patients 
had more than one source of incompetence. 
In 121 procedures (60%) 1% STD and in 80 
procedures (39%) 3% STD was used. In the remaining 
3 procedures (1%), the concentration used was not 
documented.  
The volume of sclerosant used varied between 
procedures. In 2 of the procedures (1%), 4ml of 
sclerosant was used, in 6 procedures (3%) 6ml of 
sclerosant was used, in 167 procedures (82%) 8ml of 
sclerosant was used, in 1 procedure (<1%) 16ml of 
sclerosant was used and in 28 procedures (14%) the 
amount of sclerosant used was not recorded. 
 
 
 
 
 
 
Figure 3: Anatomical site of venous incompetence 
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Figure 4: Number of procedures done on the same patient 
 
Fifty seven percent (n=117) of the procedures were 
done on the left lower limb. Forty six percent (n=93) of the 
procedures were bilateral and 54% (n=111) of the 
procedures were unilateral.  
Seventy seven (63.63%) patients had one single 
treatment session, 23 (19.01%) patients had 2 treatments, 
13 (10.74%) patients had 3 treatments, 5 (4.13%) patients 
had 4 treatments, 1 (0.83%) patient had 5 treatments, 1 
(0.83%) patient had 6 treatments, and 1 (0.83%) patient 
had 8 treatments (Figure 4). 
Complete occlusion of the veins injected with 
sclerosant occurred in 70% of procedures (n=143), partial 
occlusion occurred in 9% of procedures (n=19) and in the 
remaining 21% of procedures (n=42) this data was not 
recorded (Figure 5). Amongst patients with complete 
records 88.3% (143/162) of veins treated were completely 
occluded while 11.7% (19/162) were only partially 
occluded. Amongst patients with active ulceration 83% 
(n=29) healed their ulcer after foam sclerotherapy.  In the 
remaining 17% (n=6) of patients, the ulcer had still not 
healed at the end of follow up (Median follow up period 
11 months) (Figure 6). 
No cases of fits, transient visual disturbances, 
pulmonary embolism, deep vein thrombosis, myocardial 
infarction or cerebrovascular accidents were recorded. One 
patient (0.49%) suffered anaphylaxis soon after injection 
of sclerosant for which she was treated and made a full 
recovery. One patient complained of pruritus which was 
short lived lasting a few minutes and which resolved 
spontaneously.  
No haematomata or cutaneous ulceration occurred. 
Forty four patients (21.57%) developed skin pigmentation 
and in 1 case (0.49%), the patient experienced paraesthesia 
at the site of injection. 
 
Figure 5: Number of patients and percentages with partial 
or complete occlusion of the treated veins 
 
 
Figure 6: Number of patients and percentages with healed 
or unhealed ulcers after foam sclerotherapy 
 
 
Discussion 
The results reported in this paper indicate that 
ultrasound guided foam sclerotherapy is a useful 
treatment option for venous disease of the lower limb 
and which can be performed safely and with minimal 
complications.  The vein occlusion rate for this cohort 
was over 88% of patients which is comparable to the 
results reported in other series 
(7)
 estimated at over 
80% at 3 months. Even more rewarding was the very 
high ulcer healing rate in those treated for active 
ulceration (83%). A considerable proportion of 
patients required only one treatment session. 
The complication rate reported in our series is very 
low and it is recognised that in the vast majority of 
patients with skin staining, which was the most 
common complication, this will resolve with time and 
it is only a very small proportion of patients (1%) who 
will have permanent skin staining. 
The major advantages of foam sclerotherapy 
include the fact that it is a relatively cheap form of 
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treatment, can be done in a short time and can be done in 
an office setting without the requirement for anaesthetic or 
any specialised equipment or tools apart from the 
ultrasound scanner.  In the context of increasing demand 
on hospital beds, another considerable advantage is that 
foam sclerotherapy is performed on an out patient basis 
and compared to traditional surgery which requires at least 
day case admission, foam sclerotherapy does not take up 
any hospital beds at all. 
There is mounting evidence for the efficacy of foam 
sclerotherapy at least in the short term.  As this is a 
relatively new treatment modality the long term results are 
still being investigated.  However, even if recurrence rates 
or recanalisation rates turn out to be high in the long term, 
retreatment with sclerotherapy is still possible without any 
increase in morbidity.  There are ongoing randomised 
trials comparing the efficacy of traditional surgery, 
endovenous laser ablation and foam sclerotherapy which 
will yield more information as to the relative efficacy of 
foam sclerotherapy. The CLaSS trial is an ongoing 
multicentre randomised contolled trial comparing foam 
sclerotherapy alone, or in combination with endovenous 
laser treatment, with conventional surgery as treatment for 
varicose veins. This trial will be comparing clinical and 
cost effectiveness of the different treatment modalities and 
is due to report in 2014. A recent meta-analsyis however 
concluded that foam sclerotherapy is at least as effective as 
surgical stripping in the treatment of lower limb 
varicosities. 
(7)
 
Foam sclerotherapy is particularly useful in the 
treatment of recurrent varicose veins after surgical 
treatment.  Redo surgery for recurrent disease particularly 
in the groin as well as in the popliteal fossa is associated 
with significant morbidity, poor clinical outcomes and 
high rates of re-recurrence.  In this context the advantage 
of foam sclerotherapy is that no further surgery is required 
and the fact that the foam can be guided into small and 
tortuous veins which are not accessible to surgical 
treatment. The other major advantage of foam 
sclerotherapy is that this can be used in frail and 
elderly patients who are poor surgical candidates. 
In conclusion, this paper adds further evidence that 
foam sclerotherapy is a safe and effective treatment 
modality for lower limb venous disease.  It 
demonstrates that results obtained with foam 
sclerotherapy in Malta are similar to those reported in 
the literature.  It also confirms that high venous 
occlusion rates and ulcer healing rates can be achieved 
with foam sclerotherapy as the sole treatment modality 
for venous disease secondary to various sources of 
incompetence. 
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